Skip to content

Indaptus Therapeutics, Inc.: 10-Q filed 2025-11-12

What Indaptus Therapeutics, Inc. reported in its quarterly report filed 2025-11-12 (fiscal Q3 2025): 28 published measures, 86 facts as tagged in accession 0001493152-25-021759.

This filing

Form
10-Q (quarterly report)
Filed
2025-11-12
Fiscal period
fiscal Q3 2025
Accession
0001493152-25-021759 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All Indaptus Therapeutics, Inc. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2025-09-306,840,052USD
At 2024-12-317,338,756USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2025-09-304,605,727USD
At 2025-06-30-1,673,356USD
At 2025-03-312,799,731USD
At 2024-12-313,944,875USD
At 2024-09-306,003,326USD
At 2024-06-306,166,208USD
At 2024-03-319,360,559USD
At 2023-12-3112,076,498USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2025-09-305,825,639USD
At 2024-12-315,786,753USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2025-07-01 to 2025-09-30-2,975,117USD92
2025-01-01 to 2025-09-30-12,736,466USD273
2025-04-01 to 2025-06-30-5,228,919USD91
2025-01-01 to 2025-03-31-4,532,430USD90
2024-07-01 to 2024-09-30-3,069,036USD92
2024-01-01 to 2024-09-30-10,890,980USD274
2024-04-01 to 2024-06-30-4,015,267USD91
2024-01-01 to 2024-03-31-3,806,677USD91

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2025-01-01 to 2025-09-30-11,632,743USD273
2024-01-01 to 2024-09-30-8,927,441USD274

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2025-01-01 to 2025-09-3011,671,629USD273
2024-01-01 to 2024-09-302,946,074USD274

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2025-09-30-73,175,649USD
At 2024-12-31-60,439,183USD

Basic weighted-average shares

Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.

PeriodValueUnitDays
2025-07-01 to 2025-09-30997,038shares92
2025-01-01 to 2025-09-30689,174shares273
2024-07-01 to 2024-09-30339,659shares92
2024-01-01 to 2024-09-30315,451shares274

Diluted weighted-average shares

Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.

PeriodValueUnitDays
2025-07-01 to 2025-09-30997,038shares92
2025-01-01 to 2025-09-30689,174shares273
2024-07-01 to 2024-09-30339,659shares92
2024-01-01 to 2024-09-30315,451shares274

Basic earnings per share

Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.

PeriodValueUnitDays
2025-07-01 to 2025-09-30-2.98USD/shares92
2025-01-01 to 2025-09-30-18.48USD/shares273
2024-07-01 to 2024-09-30-9.04USD/shares92
2024-01-01 to 2024-09-30-34.53USD/shares274

Diluted earnings per share

Reported earnings or loss per share under dilution rules. Antidilutive instruments may be excluded. A diluted value can equal the basic value without implying no potential dilution.

PeriodValueUnitDays
2025-07-01 to 2025-09-30-2.98USD/shares92
2025-01-01 to 2025-09-30-18.48USD/shares273
2024-07-01 to 2024-09-30-9.04USD/shares92
2024-01-01 to 2024-09-30-34.53USD/shares274

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2025-07-01 to 2025-09-30150,614USD92
2025-01-01 to 2025-09-30572,268USD273
2024-07-01 to 2024-09-30444,184USD92
2024-01-01 to 2024-09-302,001,727USD274

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2025-07-01 to 2025-09-30-2,648,487USD92
2025-01-01 to 2025-09-30-11,677,809USD273
2024-07-01 to 2024-09-30-3,142,057USD92
2024-01-01 to 2024-09-30-11,194,181USD274

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2025-09-306,438,993USD
At 2024-12-316,618,330USD

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2025-09-302,234,325USD
At 2024-12-313,393,881USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

PeriodValueUnitDays
At 2025-09-30707,420USD
At 2024-12-31870,229USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

PeriodValueUnitDays
2025-07-01 to 2025-09-302,648,487USD92
2025-01-01 to 2025-09-3011,677,809USD273
2024-07-01 to 2024-09-303,142,057USD92
2024-01-01 to 2024-09-3011,194,181USD274

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2025-07-01 to 2025-09-301,517,723USD92
2025-01-01 to 2025-09-306,495,677USD273
2024-07-01 to 2024-09-301,466,037USD92
2024-01-01 to 2024-09-304,771,152USD274

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2025-09-301,641,920shares
At 2025-06-27604,963shares
At 2025-06-2616,946,528shares
At 2024-12-31428,799shares

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

PeriodValueUnitDays
At 2025-09-3077,764,956USD
At 2024-12-3164,379,770USD

Operating lease right-of-use asset

Carrying amount of the right to use leased assets under operating leases. It reflects discounted remaining payments, not the value of the underlying property.

PeriodValueUnitDays
At 2025-09-308,487USD
At 2024-12-3182,175USD

Operating lease liability

Present value of remaining operating lease payments. Discount-rate choices and lease terms affect the amount; it is not the sum of undiscounted future rent.

PeriodValueUnitDays
At 2025-09-308,686USD

Other noncurrent assets

Noncurrent assets the filer does not present separately. The composition differs by filer and is described only in the filing.

PeriodValueUnitDays
At 2025-09-30392,572USD
At 2024-12-31638,251USD

Prepaid expenses and other current assets

Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.

PeriodValueUnitDays
At 2025-09-30613,354USD
At 2024-12-31831,577USD

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2025-07-01 to 2025-09-301,130,764USD92
2025-01-01 to 2025-09-305,182,132USD273
2024-07-01 to 2024-09-301,676,020USD92
2024-01-01 to 2024-09-306,423,029USD274

Depreciation expense

Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.

PeriodValueUnitDays
2024-01-01 to 2024-09-30735USD274

Proceeds from issuing common stock

Cash received from issuing common stock during the period. It is gross of costs only where the filer reports it so, and it does not include noncash issuances.

PeriodValueUnitDays
2025-01-01 to 2025-09-306,396,888USD273
2024-01-01 to 2024-09-303,375,590USD274

Operating lease payments

Cash paid for operating lease liabilities during the period. It differs from lease expense recognized and excludes variable payments in some presentations.

PeriodValueUnitDays
2025-01-01 to 2025-09-3078,176USD273
2024-01-01 to 2024-09-3075,899USD274

Inspect the source

Entity
Indaptus Therapeutics, Inc. / CIK 0001857044
Captured
2026-09-21T17:31:34.871Z
SEC response SHA-256
2898ea6f398935bcc3ad1a326a712d28e35dd793acb1877cad253f0a74e7c581

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001857044.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))